SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
EMERGENT BIOSOLUTIONS
(NYSE:EBS Last Sale: 79.5 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details


NYSE: (EBS : $79.5)
$4,155,181 million Market Cap at Market Close, July 1, 2022
Biomedics SubIndustry up .00% / Health Industry up .00% Today
2273 RESEARCH BLVD Research Report Earnings Snapshot - Last 11/06/18
ROCKVILLE, MD 20850 Fact Sheet
Financial Statements
Peer Comparison

Fuad El-Hibri, CEO
Focused on the development, manufacture and commercialization of immunobiotics, such as vaccines and immune globulins, which induce or assist the body's immune system to prevent or treat disease. IPO at $12.50 November 14, 2006. Raised $62.5 million, selling 5 million shares, 18% of the outstanding. Lead Manager: J.P. Morgan.
Historical Charts    Technical Analysis
No Historical Data available for EBS

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common EBS $79.5 $79.5 0 .0 $76 $79.65 590,405 $76 $79.65 52,266,433
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock #############

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex